(NASDAQ: ALMS) Alumis's forecast annual revenue growth rate of 9.99% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 86.2%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Alumis's revenue in 2025 is $20,055,000.On average, 4 Wall Street analysts forecast ALMS's revenue for 2025 to be $2,556,651,772, with the lowest ALMS revenue forecast at $2,087,009,577, and the highest ALMS revenue forecast at $3,128,172,918. On average, 2 Wall Street analysts forecast ALMS's revenue for 2026 to be $1,069,781,025, with the lowest ALMS revenue forecast at $1,035,439,805, and the highest ALMS revenue forecast at $1,104,122,244.
In 2027, ALMS is forecast to generate $3,486,466,310 in revenue, with the lowest revenue forecast at $2,809,736,154 and the highest revenue forecast at $4,163,196,466.